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Figure 1. Cumulative incidence of relapse by CTRA gene proﬁle.
Figure 2. Probability of leukemia free survival by CTRA gene proﬁle.
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Background: Previous research suggests that patients
treated with HCT often experience elevated levels of depres-
sion and fatigue, but analyses to determine risk factors have
typically lackedstatistical power. Thegoal of the current study
was to examine sociodemographic and clinical risk factors for
depression and fatigue in a large cohort of HCT survivors.
Methods: Measures of depression (Patient Health Ques-
tionnairee 8) and fatigue (Fatigue Symptom Inventory) were
included in the annual survey of HCT recipients transplanted
at Fred Hutchinson Cancer Research Center. The survey also
included self-reported sociodemographic, health, and
medication information. Patient clinical characteristics were
obtained from the clinical database. Analyses were con-
ducted using continuous outcomes.
Results: The sample consisted of 1869 recipients (mean age
56, 53% male) with complete depression and fatigue data
(response rate of 40.8%). A total of 13% of participants
reported moderate to severe depression; 42% reported
moderate to severe fatigue. Participants were a median of 8
years from transplant (range 0.5-40 years). Depression was
signiﬁcantly associated with fatigue severity (r¼.73,
p<.0001) and fatigue disruptiveness (r¼.80, p<.0001).
Univariate analyses indicated that female gender, younger
age, chronic pain, second malignancy, allogeneic HCT, and
receipt of peripheral blood stem cells (vs. bone marrow)
were associated with greater depression, fatigue severity,
and fatigue disruptiveness (p values < .05). Among
allogeneic recipients, self-reported current and past chronic
graft-versus-host disease (GVHD) symptomatology were
associated with increased depression, fatigue severity, and
fatigue disruptiveness (p values < .05). Extent of HLA match,
myeloablative regimen, total body irradiation dose, and
patient and donor cytomegalovirus status were not
associated with depression or fatigue (p values > .05).
Multiple regression analyses using signiﬁcant univariate
predictors in the full sample indicated that female gender,
younger age, chronic pain, and receipt of peripheral blood
stem cells were independently associated with greater
depression and fatigue (p values < .05).
Conclusions: Data from the current study indicate that
females, younger patients, thosewith chronic pain, and those
who received peripheral blood stem cells are at higher risk
for fatigue and depression. The relatively high rates of
depression and fatigue in this group of survivors suggest a
high symptom burden. Better screening, referral, and
interventions are needed.
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Background: Low socioeconomic status (SES) is associated
with worse overall survival (OS) and higher transplant-
related mortality (TRM) in unrelated donor (URD)
hematopoietic stem cell transplantation (HCT) recipients
(BBMT 2009, 15:1543). A homogeneous subset of patients
from the parent study was selected and consisted of URD
myeloablative (MA) HCT recipients transplanted for acute
myelogenous leukemia (AML) in ﬁrst complete remission
(CR1). Among this group, low SES was signiﬁcantly
associated with increased expression of the conserved
transcriptional response to adversity (CTRA) gene expression
proﬁle, previously identiﬁed as also overexpressed in other
populations under conditions of chronic stress or adversity.
The purpose of the current study is to identify whether
increased CTRA gene expression may be an immunobiologic
mechanism by which pre-existing factors, such as SES, may
impact HCT outcomes.
Methods: We analyzed whether low vs. high expression of
the CTRA gene proﬁle (53 inﬂammatory, interferon-related,
and antibody-related genes) in peripheral blood mono-
nuclear cells (PBMCs) from a population of 78 Caucasian
individuals between ages 20-59 who received an URD MA
HCT for AML in CR1 is associated with signiﬁcantly different
clinical outcomes. We used the Kaplan-Meier method to
assess association with leukemia free survival (LFS) and OS
